News Conference News EAS 2023 With New LDL Goalposts in FH, Combo Therapy Must Start Early Michael O'Riordan May 29, 2023
News Conference News EAS 2021 Central and Eastern Europe Failing to Achieve LDL Treatment Targets: DA VINCI Michael O'Riordan June 07, 2021
News Conference News EAS 2020 Just One-Third of European Patients Get to LDL Cholesterol Goals Michael O'Riordan October 13, 2020
News Conference News EAS 2020 Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention Michael O'Riordan October 08, 2020
News Conference News EAS 2020 Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank Michael O'Riordan October 07, 2020
News Conference News EAS 2019 FH Patients Derive Biggest Absolute Benefit From Statin Therapy: 4S Analysis Michael O'Riordan June 03, 2019
News Conference News EAS 2019 Bempedoic Acid/Ezetimibe Combo Lowers LDL Cholesterol in High-Risk Patients Michael O'Riordan May 30, 2019
News Conference News EAS 2019 Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis Michael O'Riordan May 28, 2019
News Conference News EAS 2018 Can Clinicians Really Put a Stop to Atherosclerosis? Experts Explore the How and When of CVD Prevention Yael L. Maxwell May 07, 2018
News Conference News EAS 2018 Biology in the Back Seat: EAS 2018 Opens With Calls for a Big-Picture Approach to CVD Prevention Yael L. Maxwell May 07, 2018
News Conference News EAS 2017 Is Atherosclerosis an LDL-Cholesterol or Immune Disease? The Answer May Be Both Yael L. Maxwell April 25, 2017
News Conference News EAS 2016 Nutrition and Physical Activity: The ‘Low-Hanging Fruit’ for Cardiologists Programmed to Prescribe Pills Yael L. Maxwell June 07, 2016
News Conference News EAS 2016 Good Fats, Bad Fats, and Sugar: A ‘Big Picture’ Approach Is Warranted With Diet Interventions for Cardiovascular Disease Yael L. Maxwell May 31, 2016